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1. Introduction 
In many developed countries non-small-cell lung cancer (NSCLC), which accounts for 
approximately 85% of lung cancers, is the first cause of death in patients with malignant 
neoplasms. Depending on patients’ medical status, surgical resection is possible in early 
stages of NSCLC. Regrettably, only 15-30% of newly diagnosed NSCLC cases can be 
qualified for operation. Therefore, chemotherapy and radiotherapy plays the dominant role 
in the multidisciplinary treatment of patients with NSCLC and small-cell lung cancer 
(SCLC). Unfortunately, both options of treatment in locally advanced and metastatic lung 
cancer have limited efficacy [1]. Molecularly targeted therapies offer new possibilities of 
lung cancer treatment in genetically predisposed patients. Within the next few years, 
personalised therapy of whole lung cancer population based on screening of different gene 
mutations will become a fact. 
The development of cancer usually depends on strong carcinogenic effect of substances 
found in cigarette smoke on bronchial epithelial cells. Those carcinogens lead to genetic 
disorders that cause appearance of preinvasive changes: squamous dysplasia preceding 
carcinoma in situ and squamous cell carcinoma as well as atypical adenomatous hyperplasia 
(AAH) preceding development of adenocarcinoma. The preinvasive cells as well as cancer 
cells are characterised with large genome changes. Comparative genomic hybridisation 
(CGH) studies have identified chromosomal aberrations, particularly amplifications and 
deletions, in lung cancer cells. Cancer cells exhibit deletions of chromosome 17 short arm, 
with loss of p53 gene (deletion of 17(p12-13) and chromosome 9 short arm, with loss of p16 
gene (CDKN2A) (deletion of 9(p21-22). Both mentioned genes are suppressor genes and lack 
of their protein products allows aneuploid cancer cells to survive and accumulate serious 
chromosomal aberrations like deletions 3(p14-21), 8(p21-23), 13(q14), 13(q22-24) and allelic 
losses at 9(p21), 13(q24) as well as gains at 1(q21-31), 3(q21-22), 3(q25-27), 5(p13-14), 8(q23-
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24), 7(p12). The presence of deletions generates abnormal expression or impaired function of 
tumour suppressor genes such as RB1, FHIT, RASSF1A, SEMA3B and PTEN. However, the 
gain of chromosomal region including oncogenes is associated with overexpression or 
increased activity of MYC, KRAS, EGFR, CCDN1, MCM2, RUVBL1, SOX2 and BCL2 genes 
[2, 3]. Moreover, cell subclones with new genetic abnormalities may become dominant 
within metastases or within persistent or recurrent cancer deposits through selective 
pressures exerted by chemotherapy or molecularly targeted therapy [4]. 
Deletion of chromosome 17 short arm, with loss of p53 gene, is the most frequent 
disturbance in lung cancer (50-70%). Squamous cell carcinoma (SCC) of lung exhibits higher 
frequencies of deletions at chromosomal regions 3(p14-21), 8(p21-23), 17(p13) (p53 gene), 
13(q14) (RB1 gene), 9(p21) (CDKN2A gene) and amplification of 3(q21-22) (SOX2 gene) 
when compared with adenocarcinoma (AC). Amplification of 7(p11) and 14(q13) causing 
increased gene dosage and protein expression of thyroid transcriptional factor-1/NK2 
homeobox-1 (TITF-1/NKX2-1) and of epidermal growth factor receptor (EGFR) are prevalent 
in lung adenocarcinoma [2, 3]. 
2. Genetic mutations in lung cancer cells 
Apart of chromosomal aberrations single gene mutations can appear in lung cancer cells. 
These mutations can be revealed with molecular biology techniques. Mentioned mutations 
do not often appear simultaneously in one cancer cell (less than 3% of tumour cells). They 
concern genes important for correct proliferation, differentiation and cell growth such as 
oncogenes and genes for signal proteins involved in a complicated network of intracellular 
signal transmission (predominantly genes for tyrosine and threonine-serine kinases). 
The most important kind of genetic disturbances observed in NSCLC cells are point 
mutations (single nucleotide substitutions), small (few to a few dozen base pairs) deletions 
or insertions and formation of fusion genes as a result of translocation of gene fragments, 
usually within a single chromosome. Some of these alterations change the structure of 
proteins (sense mutations) which play an important role in oncogenesis, others shift the 
expression of oncogenes and suppressor genes, while some remain silent. Such processes 
lead to protein malfunction: they can increase or decrease protein expression or cause 
differences in normal enzyme activity. 
Accumulation of driver mutations in different genes is detected depending on history of 
tumour exposure to carcinogens. Failure of DNA repair and progressive genetic instability 
leads to appearance of mutation that drives cancer development, its growth and metastases 
[4]. Molecular type of lung cancer is partially consistent with histological type of tumour. 
Although frequency of occurrence of some driver mutations is extremely rare, in only 20% 
of NSCLC tumours important mutations are not detected. Small cell lung cancer is less 
characterised in terms of incidence of genetic mutations. Until 2011, 1738 mutated genes and 
tens of thousands of different types of mutations were identified in NSCLC [2, 5, 6, 7]. 
Figure 1 shows the percentage of tumours with identified mutations in all histological types 
of NSCLC. 
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Figure 1. The percentage of NSCLC tumours with identified mutations in different genes (EGFR gene 
amplification and polysomy, as well as p53 gene abnormalities which are common in NSCLC tumours 
have not been included on the graph). 
NSCLC is a heterogeneous aggregate of histological subtypes, which traditionally have been 
grouped together because of similarities of treatment outcome. Ideally, a tumour 
classification system should include morphologic and genetic distinctions between tumour 
types, which will help to define specific subset of patients responsive to certain molecularly 
targeted treatment. In terms of genetic mutations squamous cell carcinomas are the least 
described. Mutations have not been detected in over 50% of already screened tumours (Fig. 
2). On the other hand adenocarcinoma cases are definitely better described and in only 20% 
of tumours screening fails to describe any mutations. Among 10-15% of non-smokers (but 
also light-smokers and former smokers) adenocarcinoma might develop regardless of 
tobacco smoking. In these cases in almost all tumours different genetic mutations have been 
found, mostly in epidermal growth factor receptor (EGFR) and KRAS genes as well as 
presence of EML4-ALK fusion gene (Fig. 3). Accumulated evidence suggested that lung 
cancer in ever smokers and never smokers follow distinct molecular pathways and may 
therefore respond to distinct therapy. One could speculate than non-small cell lung cancer in 
ever and never smokers are two distinct disorders regarding their molecular level and the 
manner of treatment planning [5, 6, 7, 8, 9, 10, 11, 12]. 
The most frequent irregularity found among squamous cell carcinoma patients is an 
amplification of gene for fibroblast growth factor receptor type 1 (FGFR) and p53 gene 
abnormalities. These disturbances could overlap with other mutations. In SCC it is 
extremely rare to detect EGFR, PTEN, ERBB2 (HER2), PIK3CA, DDR2 or BRAF mutations, 
which are more typical for adenocarcinoma [5, 6, 7]. 
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Figure 2. The percentage of SCC tumours with identified mutations in different genes (p53 gene 
abnormalities which are common in SCC tumours have not been included on the graph) 
 
 
Figure 3. The percentage of AC tumours with identified mutations in different genes (EGFR gene 
amplification and polysomy have not been included on the graph). 
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Among patients with adenocarcinoma the most often detected irregularities are in EGFR 
gene, Kirsten rat sarcoma viral oncogene homolog (KRAS) gene and p53 gene. In non-
smoking Caucasian population activating mutations in EGFR gene appear with frequency of 
over 50%. The most common mutations in this gene are: small (9-21 base pair) deletions in 
exon 19 (48% of detected mutations) and missense mutations in exon 21 (L858R, 41% of 
detected mutations). Substitutions in exon 18-21 or insertions and duplications in exon 20 
are rare but they also appear [2, 9, 13]. 
Mutations in exon 18-21 of EGFR gene concern tyrosine kinase domain of the EGF receptor. 
Overexpression of EGFRs’ tyrosine kinase function leads to hyperphosphorylation of 
intracellular signalling proteins of Pi3K/Akt or RAS/RAF/MAPK pathways without having 
to activate the receptor with its specific ligand – the EGF. The activation of Pi3K/Akt 
pathway results in stimulation of transcription factors such as STAT or excessive 
proliferation of cancer cells. Mutations in EGFR gene are most common in papillary AC, less 
frequent in adenocarcinoma with „lepidic predominant” growth and least frequent in solid 
AC [2, 13].  
Mutations in KRAS gene are also common and are detected in 15-25% of adenocarcinoma 
cases. KRAS gene, which is coding a low molecular weight guanosine triphosphatase 
(GTPase) is considered to be the most frequently mutated oncogene in lung AC arising in 
patients with history of smoking. Most KRAS mutations involve replacing glycine with 
other amino acids such as valine, aspartic acid and glutamic acid in codon 12. Less frequent 
mutations consider codon 13 and 61. The emergence of the mutation causes the reduction of 
GDPase activity with subsequent potent activation of mitogenic and proliferative signalling 
through the RAF/MEK/ERK/MAPK cascade. Mutations in KRAS gene are most common in 
solid mucinous adenocarcinoma and in acinar adenocarcinoma [2, 5, 6, 7]. 
Among other mutations detected in more than 2% of adenocarcinomas are EML4-ALK 
fusion gene, substitution V600E in BRAF oncogene, substitutions in codon 542, 545 and 1047 
of PIK3CA oncogene, insertion in exon 20 of ERBB2 gene, polysomy of FGFR1 gene and 
amplification of cMET gene. Both anaplastic large cell lymphoma kinase (ALK) and 
echinoderm microtubule associated protein 4 (EML4) genes are located in chromosome 2p 
and fusion of both involves small inversions within this region. EML4-ALK fusion results in 
constitutive activation of ALK kinase. EML4-ALK fusion gene is prevalent in lung 
adenocarcinoma (2-4%), especially in signet ring cell carcinoma (<15%), in younger patients 
and in never- or light smokers. EML4-ALK fusion gene is mutually exclusive with EGFR and 
KRAS gene mutations. Recently, new fusion genes have been discovered in lung 
adenocarcinomas, including fusion of kinesis family member 5B (KIF5B) with ret proto-
oncogene (RET) and fusion of coiled-coil domain containing protein 6 (CCDC6) with RET as 
well as fusions of ALK with c-ros oncogene 1 receptor tyrosine kinase (ROS1) [2, 5, 6, 7, 14, 
15]. 
Information about the mutations mentioned above come from large databases such as 
Catalogue of Somatic Mutations in Cancer (COSMIC), My Cancer Genome, The Cancer Genome 
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Atlas and the results obtained by the American Lung Cancer Mutation Consortium (LCMC) [5, 
6, 7, 16]. 
3. Molecular biology methods in lung cancer diagnostics 
Mutation testing has become an essential determinant in clinical practice in decision of 
treatment options for patients with non-small-cell lung carcinomas. Unfortunately NSCLC 
tumours, in which the molecular diagnostics is carried out, are highly heterogeneous and 
the cytological and histological material is often insufficient to complete the analysis (small 
percentage of cancer cells or DNA fragmentation in the process of paraffin embedding). 
Direct sequencing is still a frequently used method despite having low sensitivity and being 
time-consuming and labour-intensive. However, direct sequencing and particularly next 
generation sequencing (technology based on reversible dye terminators, sequencing by 
ligation and pirosequencing) are the methods of high-throughput screening for unknown 
mutations. Microarrays containing oligonucleotide mutation probes are emerging as useful 
platforms for the diagnosis of multiple genetic abnormalities in cancer cells [17, 18]. 
The multiplex SNaPshot PCR (minisequencing) technique is a PCR (polymerase chain 
reaction)-based assay for detection of known mutations. Specific primer which anneals 
immediately adjacent to the mutated region is extended by one base using a fluorescently 
labeled ddNTPs, which are detected in capillary electrophoresis. No further extension is 
possible because of the ddNTP binding. This kind of reaction is being used more and more 
frequently because of its fast and sensitive detection of many known mutations in a single 
assay [19]. 
Recent advances in molecular techniques have enabled the design of sensitive detection 
assays based on quantitative real-time PCR, but usually with limited degree of mutation 
coverage. Allele-specific PCR (ASP-PCR), amplification refractory mutation system PCR 
(ARMS-PCR), clamp PCR and mutant-enriched PCR (ME-PCR) are among these techniques. 
The most frequently used is the ARMS–PCR method that can detect a known SNP (single 
nucleotide polymorphism). It consists of two complementary reactions: one containing an 
ARMS primer specific for the normal DNA sequence that cannot amplify mutant DNA at a 
given locus and the other one containing a mutant-specific primer that cannot amplify 
normal DNA. High resolution melting (HRM) real-time PCR is also a technique that might 
allow fast screening for mutations. The real-time PCR technology itself is highly flexible and 
many alternative instruments and fluorescent probe systems have been developed recently 
[17, 18]. 
For detecting polysomy, gene amplifications and the presence of fusion genes molecular 
probes labelled with different fluorochromes and fluorescence in situ hybridisation (FISH) 
technique are being used. Techniques related to FISH, but allowing to label only one gene 
fragment, are silver in situ hybridisation (SISH) and chromogenic in situ hybridisation 
(CISH). The FISH technique requires an assessment of signal quantity from labelled genes 
and chromosome fragments with fluorescence microscopy whereas SISH or CISH staining 
can be analysed in light microscope [17, 18]. 
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Routine genetic testing for somatic mutations in lung cancer biopsies is becoming the 
standard for providing optimal patients care. However, it is unclear whether this testing 
should be routine for all lung cancer patients, because the prevalence of the most common 
mutations is very low especially in heavy smokers with squamous cell carcinoma. 
Moreover, great number of molecular biology methods and variety of biological material 
acquired from patients create a critical need for robust, well-validated diagnostic tests and 
equipment that are both sensitive and specific for mutations. An In Vitro Diagnostic Medical 
Device (IVD) is defined in Directive 98/79/EC of European Parliament and of the Council. 
IVD is described as any medical device which is a reagent, calibrator, control material, kit, 
equipment or system, whether used alone or in combination, intended by the manufacturer 
to be used in vitro for the examination of specimens, including blood and tissue donations, 
derived from the human body for the purpose of providing information concerning 
pathological state and congenital abnormalities of patients as well as to monitor therapeutic 
effect. IVD equipment is labelled by CE marking according to European Product Safety 
Regulations [20]. 
4. Molecularly targeted therapies in lung cancer 
Molecularly targeted drugs are directed against abnormal proteins and other molecules, 
specific for cancer cells, participating in metabolic pathways. Excess activation of those 
pathways is essential for growth and unrestrained proliferation of cancer cells. Blocking 
these pathways results in inhibition of cell division and in cell apoptosis. Therefore, 
molecularly targeted drugs show high efficacy in two groups of patients: 
1. if the mutation of the gene encoding a signalling pathway protein results in excessive 
activity while changing its structure, what allows more effective binding of the drug 
(e.g. activating mutations in EGFR gene and the efficacy of tyrosine kinase inhibitors of 
EGFR), 
2. if the mutation of the gene encoding a signalling pathway protein results in excessive 
activity of the pathway and its blocking, regardless of the matching of the drug to the 
target protein, impairs tumour cell proliferation, which can be achieved at two levels: 
a. direct blocking of abnormal protein 
b. blocking of subsequent signalling pathway proteins stimulated by the abnormal 
protein [21]. 
Therefore, many of the therapies currently under development target several signalling 
proteins, especially tyrosine kinase receptors (e.g. EGFR, HER2, HER3, IGF-1R, cMET) or 
proteins in downstream signalling pathway (RAS/RAF/MAPK/mTOR and Pi3K/AKT) [19, 
21]. 
Excessive stimulation of epidermal growth factor receptor increases proliferation of cancer 
cells in different kinds of tumours, i.a. in non-small-cell lung cancer. Cell growth signal is 
transmitted from EGFR (HER1), after its heterodimerisation with other member of HER 
family (ERBB2 – HER2, HER3 or HER4), through phosphorylation of Pi3K/AKT and 
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RAS/RAF/MAPK/mTOR pathway. The phosphorylation takes place due to EGFR tyrosine 
kinase activity, which performs hydrolysis of ATP to ADP and free phosphate. Tyrosine 
kinases are a part of EGFR but also other cell receptors and signalling proteins. 
Phosphorylation disorder initiated by EGFR tyrosine kinase is associated with the 
development of NSCLC that is independent from tobacco smoke carcinogens. Blocking of 
EGFR function may be achieved by using small molecule tyrosine kinase inhibitors (TKI) or 
monoclonal antibodies (such as cetuximab), which bind to extracellular domain of EGFR. 
Inhibition of tyrosine kinase function by TKI-EGFR is much more effective if the amino acid 
structure of the enzyme is disrupted by activating mutations in EGFR gene (described in the 
previous section). Cetuximab on the other hand demonstrates better effectiveness when 
high expression of EGFR is present on cancer cell surface [2, 9, 11, 12, 21, 22]. 
At the moment, two reversible EGFR TKIs are in use: gefitinib and erlotinib. Phase III study 
IPASS, carried out among Asian patients (up to 40% of EGFR gene mutation NSCLC 
carriers), has proven higher efficacy of gefitinib (71,2% response rate, longer progression 
free survival (PFS) up to 12 months and significant improvement in quality of life, but 
without overall survival (OS) prolongation) in compare to chemotherapy consisting of 
carboplatin and paclitaxel in patients with activating EGFR gene mutations. However, 
among patients with wild type EGFR gene, first line chemotherapy of advanced NSCLC 
with gefitinib was ineffective. The study included more than 1 200 adenocarcinoma patients, 
with a retrospective biomarker analysis performed on specimens from 437 tumour samples 
with evaluable EGFR gene mutation data. Mutations in EGFR gene were identified in 261 
(59,7%) of these patients. Later studies comparing efficacy of erlotinib or gefitinib and 
standard chemotherapy had proven that EGFR TKIs are effective in first line of treatment 
(NEJ 002, WJTOG 3405, OPTIMAL, EURTAC studies) but only in patients with activating 
mutations in EGFR gene (Table 1). Moreover, OPTIMAL study showed that patients with 
deletion in exon 19 had longer median PFS than those with substitution L858R in exon 21 of 
EGFR gene. However, IPASS and WJTOG 3405 studies have not proven these observations 
[2, 11, 12, 21, 22, 23]. 
The BR.21 study concerned the effectiveness of erlotinib monotherapy in second or third line 
therapy in patients with advanced NSCLC. Erlotinib has prolonged PFS and improved 
quality of life when compared to best supportive care in the whole patients group, but an 
objective response was achieved in only 10% of patients. Patients with EGFR gene 
amplification, detected with FISH technique, responded more frequently to therapy with 
erlotinib. 61 (38,4%) of 159 tumours analysed in BR.21 study were positive for an increased 
EGFR gene copy number. Response rates were 21% and 5% in patients who were FISH-
positive and FISH-negative, respectively. This benefit seemed to extend to survival 
(HR=0,43; p=0,004). It is not certain, if this result was related with underestimation of EGFR 
gene mutations in FISH-positive patients due to the use of sequencing method for EGFR 
gene mutation analysis. The INTEREST study confirmed this suggestion, demonstrating the 
superiority of gefitinib over docetaxel in second line of treatment in patients with activating 
mutation of EGFR gene. Application of reversible TKI-EGFR in II and III line of treatment in 
patients without activating mutations in EGFR gene is controversial [2, 11, 12, 21, 22, 23].  
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Study 
Patients with 
mutation 
Treatment arms 
Response 
rate 
Median 
PFS 
PFS 
(favouring 
TKI-EGFR) 
IPASS 
216 Asian 
patients 
gefitinib vs. 
paclitaxel/carboplatin 
71% vs. 
47% 
9,5 vs. 6,3 
months 
HR=0,48 
(95% CI: 0,36-
0,64) 
JP 0056 
(NEJ 002) 
200 North-
East Japan 
patients 
gefitinib vs. 
paclitaxel/carboplatin 
74% vs. 
31% 
10,8 vs. 5,4 
months 
HR=0,31 
(95% CI: 0,22-
0,41) 
WJTOG 
3405 
177 Asian 
patients 
gefitinib vs. 
docetaxel/carboplatin 
62% vs. 
32% 
9,2 vs. 6,3 
months 
HR=0,49 
(95% CI: 0,34-
0,71) 
OPTIMAL 
165 Asian 
patients 
erlotinib vs. 
gemcitabine/carboplatin
83% vs. 
36% 
13,1 vs. 4,6 
months 
HR=0,16 
(95% CI: 0,10-
0,26) 
EURTAC 
170 Caucasian 
patients 
erlotinib vs. platinum 
doublet 
58% vs. 
15% 
9,7 vs. 5,2 
months 
HR=0,42 
(95% CI: 0,27-
0,64 
Table 1. Prospective, randomised studies of efficacy of first-line TKI-EGFR and standard chemotherapy 
in patients with EGFR gene mutations [12]. 
The phase III SATURN study was designed to examine the effect of erlotinib in 
maintenance therapy dedicated to patients who had clinical benefit after 4 cycles of 
standard chemotherapy. PFS was significantly prolonged (HR=0,71; p<0,0001) and 
response rate (11,9% vs. 5,4%) was improved with erlotinib compared to best supportive 
care in all patients. However, significantly prolonged PFS was observed with erlotinib 
mainly in group of patients whose tumours had EGFR mutation (HR=0,10; p<0,0001) [2, 11, 
12, 23]. 
Although controversial clinical trial results, National Comprehensive Cancer Network 
(NCCN) recognises that the presence of EGFR-activating mutations represents a “critical” 
biomarker for appropriate patients selection for TKI-EGFR therapy [24].  
Some genetic irregularities may be responsible for occurrence of primary or secondary 
resistance to reversible TKI-EGFR and disease progression even after more than ten months 
of therapy. EGFR wild-type gene and KRAS gene mutations are associated with intrinsic 
TKI-EGFR resistance. Moreover mutations in KRAS and EGFR genes do not occur 
simultaneously in the same cancer cell. Patients with mutated KRAS gene experience better 
PFS with standard chemotherapy than with TKI-EGFR therapy. However, a subgroup of 90 
patients from SATURN study who had KRAS mutation showed no significant difference in 
PFS in erlotinib-arm and placebo-arm. Although KRAS mutation has been associated with 
clinical outcomes with cetuximab in colorectal cancer, no association was reported from 
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analyses of clinical studies of cetuximab in combination with chemotherapy in patients with 
NSCLC. Currently, KRAS mutation testing is not recommended in molecular diagnosis of 
NSCLC patients [11, 12].  
The secondary resistance to reversible TKI-EGFR is connected with the inability to extend 
overall survival with erlotinib or gefitinib therapy. Underlying mechanism of resistance to 
reversible EGFR TKIs is an amplification of IGF1R and MET gene, but also mutations in 
exon 20 of EGFR and HER2 genes. The presence of such abnormalities may have a pivotal 
role in qualification to novel therapies, currently in their last phase of clinical trials. 
Inhibitors of insulin-like growth factor receptor 1 (IGF1-R), both small molecule as well as 
monoclonal antibodies, and inhibitors of receptor for hepatocyte growth factor (cMET) (e.g. 
tivantinib – ARQ-197 or MetMab) may be used in some patients treated with reversible TKI-
EGFR among whom a resistance for the therapy has occurred as an alternative way of 
Pi3K/AKT pathway stimulation created through overexpression of IGF1R and cMET (Figure 
4) [25, 26, 27]. 
The occurrence of T790M mutation in exon 20 of EGFR gene and mutations in exon 20 of 
HER2 gene may be important for the proper qualifications for the treatment with 
irreversible EGFR TKIs. Drugs like afatinib (BIBW-2992), PF-00299804 or neratinib (HKI-
272) may be effective in case of resistance to reversible TKI-EGFR when a secondary 
mutation is present (e.g. T790M). The action of afatinib remains until the EGFR protein is 
removed from the cancer cell surface. Furthermore, afatinib also blocks HER2 and HER4 
proteins which are preferential heterodimerisation partners for EGFR during stimulation 
by EGF. In LUX-Lung 1 study, afatinib efficacy (prolongation of PFS) was proven as a 
rescue treatment after failure of erlotinib or gefitinib if duration of second-line TKI-EGFR 
treatment exceeded 24 weeks (HR=0,38, p<0,0001). Irreversible TKI-EGFR may also be more 
effective than reversible TKI-EGFR in first-line of treatment of patients with activating 
mutations of EGFR gene. In the LUX-Lung 2 study, 129 patients with activating EGFR 
mutations and no previous TKI-EGFR treatment received afatinib as a single agent. Overall 
response rate was 60% with a promising PFS of 14 months. LUX-Lung 3 and LUX-Lung 6 
studies are designed to compare effectiveness of afatinib and chemotherapy based on 
pemetrexed and cisplatin or gemcitabine and cisplatin in patients with EGFR mutations. As 
first-line treatment of patients with known EGFR mutation, PF-00299804 showed 
encouraging efficacy, which exceeded the erlotinib effectiveness. In patients with T790M 
and T854A mutations in EGFR gene, the combination of irreversible TKI-EGFR therapy 
with application of monoclonal antibody against EGFR (cetuximab) may be also reasonable 
[11, 12, 25, 26, 27].  
Big hopes for the development of lung adenocarcinoma therapy are related to phase III 
studies over a novel, small molecule, molecularly targeted drug – crizotinib, an inhibitor of 
ALK, ROS1 and cMET. Crizotinib is particularly active in patients with EML4-ALK fusion 
gene, inducing disease control in up to 90% of such patients and prolonging their overall 
survival. In patients with EML4-ALK fusion gene, 64% of patients treated with crizotinib 
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survived more than 2 years and 77% of patients survived more than 1 year. Newly defined 
kinase fusions (KIF5B with RET and ROS1 with ALK and with other fusion partners) may be 
also promising targets for molecular therapies [11, 12, 14, 15, 26, 27]. 
 
 
 
 
 
 
Figure 4. EGFR pathway components and possibility of new molecularly targeted therapies application 
in resistance to reversible TKI-EGFR. 
Drugs inhibiting neoangiogenesis within the tumour have also found an application in 
molecularly targeted therapy of patients with NSCLC. These drugs are bevacizumab – a 
monoclonal antibody directed against vascular endothelial growth factor (VEGF) and small 
molecule drugs, inhibiting tyrosine kinase functions of VEGFR, PDGFR, FGFR, RET and c-
Kit (vargatef, sunitinib) [26, 27] 
American Lung Cancer Mutation Consortium (LCMC) had screened NSCLC tumour samples 
not only for EGFR and ALK mutations, but also for other known mutations such as KRAS, 
EGFR, EML4-ALK, BRAF, HER2, PIK3CA, NRAS, MEK1, AKT1 and MET gene irregularities. 
 
Mutations in Human Genetic Disease 212 
Mutations were found in 54% (280/516) of completely tested tumours, in 15 certified 
genetic laboratories. Mutation screening is not only for research purposes, but is also 
designed to determine patients who might benefit from molecularly targeted therapies. 
Molecular testing could definitely identify the mutations associated with response or 
resistance to targeted therapies [16]. Nowadays, we have an opportunity to match 
molecularly targeted therapies with the structure of proteins that are taking part in 
signalling pathways of neoplasm cells. The efficiency of tyrosine kinase inhibitors of EGFR 
(erlotinib, gefitinib) and ALK (crizotinib) in NSCLC patients bearing EGFR or ALK 
activating mutations is the example of such relationship. These observations create new 
possibilities for personalisation of known molecularly targeted therapies (registered and 
tested in clinical trails) in large population of NSCLC patients [16]. LCMC idea was used to 
describe potential capability of therapy of NSCLC patients, based on presence of mutations 
in cancer cells. Similarly, the BATTLE program at the M.D. Anderson Cancer Centre in 
Houston assessed biomarker-guided treatment in patients with previously treated, 
advanced NSCLC and biopsy-amenable disease. For this purpose, cancer gene databases 
should be created to determine what is known about germline and somatic gene variants 
as well as treatment options and their outcomes. According to recent cancer genomic 
knowledge, clinical trials of novel molecularly targeted drugs, could be offered to cancer 
patients who are unlikely to benefit from a standard therapy, with relatively poor 
prognosis and to patients who are more likely to benefit from a novel therapy due to the 
presence of tumour genetic abnormalities that predict sensitivity, lack of resistance or 
toxicity of a treatment (Table 2) [4, 16, 19, 26, 27]. 
 
Genetic abnormality Treatment Mechanism of action
activating mutation 
of EGFR 
erlotinib or gefitinib small molecule, reversible TKI-EGFR 
activating mutation 
of EGFR 
erlotinib + OSI-906 or 
MM-121 or MK-0646 
small molecule, reversible TKI-EGFR + 
small molecule TKI IGF-1R or fully human 
monoclonal antibody against ErbB3 
KRAS mutation; 
MET amplification 
erlotinib + tivantinib 
(ARQ-197) or 
onartuzumab (MetMAb); 
JTP-74057 (GSK1120212); 
small molecule TKI-EGFR + small molecule 
TKI cMET or monovalent (one-armed) 
monoclonal antibody against cMET; small 
molecule inhibitor of MEK 1/2 
serine/threonine kinase;  
fusion gene EML4-
ALK and fusion 
genes with ROS1 
gene component; 
ROS1 mutation 
crizotinib, AP-26113, 
LDK-378, AF-802 
small molecule TKI of ALK, ROS1 and 
cMET; small molecule TKI of ALK and 
EGFR; small molecule TKI of ALK 
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NRAS, MEK1 or 
BRAF mutation 
GSK-1120212 
small molecule inhibitor of MEK 1/2 
serine/threonine kinase 
BRAF, NRAS 
mutation 
GSK-2118436; 
vemurafenib (PLX-4032) 
small molecule inhibitor of BRAF 
serine/threonine kinase 
mutation in exon 20 
of EGFR (e.g. 
T790M); HER2 
mutation 
Afatinib (BIBW2992), 
neratinib, PF299804, CI-
1033, EKB-569, AV-
412/MP-412, lapatinib 
small molecule, irreversible TKI of pan-
HER; small molecule, irreversible TKI of 
EGFR and HER2 
PIK3CA mutation 
BEZ-235, GDC-0491, 
SAR-245409, BKM-120, 
BYL-716, OSI-027, PX-
866, MK-8669 
small molecule inhibitor of mTOR and 
PI3K kinases; small molecule inhibitor of 
pan-PI3K; small molecule selective 
inhibitor of PI3Kα 
MEK1 mutation 
JTP-74057 (GSK-
1120212); selumetinib 
(AZD-6244), GDC-0973, 
MEK-162, MSC-1936369B
small molecule inhibitor of MEK 1/2 
serine/threonine kinase (MAPK/ERK 
kinase1/2 kinases); 
DDR2 mutation 
(S768R)  
erlotinib + dazatinib or 
nilotynib 
small molecule inhibitor of BCR-ABL, SRC, 
c-Kit, EPH and PDGFRβ  
FGFR amplification 
PD-173074, ponatinib 
(AP24534), BGJ-398, FP-
1039 
small molecule TKI of FGFR and VEGFR; 
small molecule kinase inhibitor of native 
and mutated BCR-ABL, VEGFR2, FGFR1, 
PDGFRα, mutated FLT3 and LYN; small 
molecule TKI of FGFRs; monoclonal 
antibody against FGFR1 
PDGFR 
amplification, 
PDGFR mutation, c-
Kit mutation 
MEDI-575, IMC-3G3, 
sunitinib, sorafenib, OSI-
930, pazopanib (votrient)
Monoclonal antibody against PDGFR α; 
small molecule inhibitors of kinases of 
VEGFR1-3, RET, c-Kit, PDGFR α and β 
FGFR and/or PDGFR 
amplification 
intedanib (BIBF-1120), 
dovitinib (TKI258) 
small molecule inhibitor of angiokinase 
(FGFR, PDGFR, VEGFR) 
BRCA1 deficiency olaparib + cisplatin 
small  molecule inhibitor of poly(ADP-
ribose) polymerase (PARP) 
AKT1 mutation MK-2206, GSK-2110183 AKT inhibitors 
Table 2. An example of qualification possibilities for molecularly targeted therapies based on NSCLC 
cell molecular signature (in most countries gefitinib, erlotinib and crizotinib are the only registered 
drugs in NSCLC therapy; other indications for therapy are hypothetical and are based only on the 
results of early clinical trials). 
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5. Summary 
It is worth remembering that the presence of mutations may overlap with much more severe 
genetic abnormalities of lung cancer cells. These irregularities result in profound changes in 
cancer cells ability to proliferate and in effect it becoming invulnerable to selective 
molecularly targeted therapies. Therefore, at present only few above mentioned drugs may 
be used in lung cancer patients instead of standard chemotherapy. In most cases, 
molecularly targeted therapies will find an application in patients who have already 
exhausted all standard chemotherapy forms.  
Multiple genetic alterations in lung cancer tumours and different targeted therapies based 
on appropriate molecular status of patients are still under investigation. However, the 
problems with proper obtaining and storage of tumour tissue for molecular testing as well 
as choosing adequate molecular methods for gene mutation screening is still open for 
discussion. 
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